Ed Miseta - Chief Editor, Clinical Leader & Outsourced Pharma

Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ED'S WORK

Morphogenesis_450x300.jpg
Pets, Perseverance, And Manufacturing Facility Bring Biotech Success
Patricia Lawman, cofounder and CEO of the biotech firm Morphogenesis, explains the company’s unlikely genesis and different approach to animal testing.  Continue Reading..
Felxion_450x300.jpg
How Flexion Pivoted To Become A Commercial Biotech
Unfortunately, Flexion’s incorporation coincided with the financial crisis of 2007-2008, and the assumption that large pharma’s would pay premiums for successful proof of concept assets came under pressure.  Continue Reading..
Lilly_Lotus Mallbris_450x300.jpg
The Benefits & Challenges Of Head-To-Head Trials
In Lilly’s immunology portfolio, eight different H2H clinical trials have been conducted thus far. Four of those trials were conducted in parallel with a Phase 3 trial and four were conducted after it. Although the benefits are attractive to a sponsor company, H2H trials can present some unique risks.  Continue Reading..
Aerami Therapeutics_Anne Whitaker_450x300.jpg
A Quick Transition From Research Firm To Clinical-Phase Biotech
Since Oct. 2018, Anne Whitaker had to figure out how to transition Aerami Therapeutics from a research firm to a clinical-phase company. It’s been a complicated and challenging journey.  Continue Reading..
01_FromThe CRO 0517_450by300
DIA And CRO Leadership Awards Go Virtual
The team behind DIA’s Annual Meeting was able to put together an event that was as informative and engaging as past years, despite the short and very hectic time frame. More than 200 sessions took place virtually, with 120 of those being on demand.  Continue Reading..
Paratek_450x300.jpg
Why Is Antibiotic Development In The U.S. Disappearing?
Today, 95 percent of antibiotics in development are being studied by smaller biotechs, including Paratek Pharmaceuticals. Today, the company is on a strong trajectory, but its ups and downs show why antibiotic companies fail and few new antibiotics reach patients.  Continue Reading..
Telehealth Remote Clinical Trial
COVID-19 & The Virtual Trial Rush: Front-Line Insights
The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.  Continue Reading..
Lilly Stop Coronavirus Clinical Trials
Lilly Slams The Brakes On New Clinical Trial Activity
Conducting clinical trials during the COVID-19 pandemic is no easy task. Recognizing this unfortunate change in events caused by COVID-19, Eli Lilly and Company has made the difficult decision to delay most new clinical study starts and pause enrollment in most ongoing studies.  Continue Reading..
Millendo_450x300
A Biopharma That Had To Pivot Twice To Forge Ahead
Not many thriving companies experience disappointing clinical trial results, jump into an entirely new therapeutic area, and emerge with investor support and renewed hope for an entirely different class of patients. Millendo has done it twice.  Continue Reading..
IST Clinical Trials -Martin Lehr_450x300
A Small Biopharma That Doesn’t Use CROs
When it comes to conducting clinical trials, most emerging companies choose to access external resources through partnering with CROs. That is what makes Martin Lehr, CEO of Context Therapeutics different. He prefers to bypass CROs and take part in Investigator-Sponsored Trials (ISTs).  Continue Reading..